Clinical significance of dual time point 99mTc-sestamibi breast-specific gamma imaging and 18F-FDG PET/CT for discriminating breast cancer

1053Objectives: We compared 99mTc-sestamibi breast specific gamma imaging (BSGI) and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) to determine their clinical value in differentiating malignant breast lesions and discriminating between two malignant subtypes, invasive ductal carcinoma (IDC) and ductal carcinoma in situ (DCIS).Methods: A total of 224 patients who underwent preoperative DTP BSGI and 18F-FDG PET/CT between November 2010 and April 2014 were studied. All primary lesions were histopathologically confirmed as IDC or DCIS. BSGI and PET/CT results were compared with the final histopathologic diagnoses based on surgical reports. The benign histopathologic analysis was performed on specimens acquired by ultrasonography (US) guided needle biopsy or surgical procedure (e.g., excision). Tumor-to-normal background ratio (TNR) of early (TNR1) and delayed (TNR2) BSGI were acquired by measuring the number of uptake counts of the primary lesion and normal background breast tissue, respectively. The percent changes in TNR (% TNR) were computed for the images by subtracting TNR1 from TNR2 and dividing by TNR1. For quantitative assessment of PET/CT data, the maximal standardized uptake value (SUVmax) was measured. The SUVmax of early images (SUVmax1) and delayed images (SUVmax2) were obtained. Thereafter, the percent changes in SUVmax (% SUVmax) were calculated by subtracting SUVmax1 from SUVmax2 and dividing by SUVmax1. To estima...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Breast Cancer Posters Source Type: research

Related Links:

Abstract PURPOSE: To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR) testing in breast cancer guideline. METHODS: A multidisciplinary international Expert Panel was convened to update the clinical practice guideline recommendations informed by a systematic review of the medical literature. RECOMMENDATIONS: The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no...
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Tags: J Clin Oncol Source Type: research
Abstract PURPOSE.—: To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer guideline. METHODS.—: A multidisciplinary international Expert Panel was convened to update the clinical practice guideline recommendations informed by a systematic review of the medical literature. RECOMMENDATIONS.—: The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benef...
Source: Archives of Pathology and Laboratory Medicine - Category: Laboratory Medicine Authors: Tags: Arch Pathol Lab Med Source Type: research
CONCLUSIONS: There was no relationship between FoxP3+ TIL numbers and cancer progression as reflected in tumor size and axillary lymph node in patients with SBBC. Aggressive biological factors, especially high NG, were significantly related to enhanced recruitment of FoxP3+ TILs. PMID: 31933123 [PubMed - as supplied by publisher]
Source: Breast Cancer - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research
AbstractPurpose of ReviewWe aim to review the appearance of ductal carcinoma in situ (DCIS) across the spectrum of imaging modalities used in common clinical practice.Recent FindingsChanges in technology and clinical breast cancer screening patterns have impacted the imaging evaluation of DCIS. DCIS classically presents as asymptomatic calcifications in women undergoing screening mammography. The replacement of traditional 2D mammography with digital breast tomosynthesis has changed the typical appearance of screen-detected DCIS. Ultrasound is traditionally utilized to detect DCIS in women with clinical symptoms, but effor...
Source: Current Breast Cancer Reports - Category: Cancer & Oncology Source Type: research
ConclusionsBreast cancer risk among women with LCIS is impacted by breast density. These results aid in personalizing risk assessment among women with LCIS and highlight the importance of chemoprevention counseling for risk reduction.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: Targeting mTORC1 can inhibit DCIS progression to IDC via MMP9 and may be a potential strategy for DCIS or Early-Stage IDC therapy. PMID: 31871301 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
FRIDAY, Dec. 20, 2019 -- For women with primary ductal carcinoma in situ (DCIS), use of radiotherapy (RT) is associated with increased rates of breast cancer-specific mortality for those women who subsequently develop an invasive second breast...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
The progression of ductal carcinoma in situ (DCIS) into invasive ductal carcinoma (IDC) is prevented by normal breast myoepithelial cells. Studies have suggested that EMT-associated genes were enriched in IDC ...
Source: Cancer Cell International - Category: Cancer & Oncology Authors: Tags: Primary research Source Type: research
Biological markers that could predict the progression of ductal carcinoma in-situ (DCIS) to invasive breast cancer (IDC) are required urgently for personalized therapy for patients diagnosed with DCIS. As stroma was invaded by malignant cells, perturbed stromal-epithelial interactions would bring about tissue remodeling. With the specific expression of the fibroblast activation protein-alpha (FAP-a), Carcinoma-associated fibroblasts (CAFs) are the main cell populations in the remodeled tumor stroma. Golgi phosphoprotein 3 (GOLPH3), a documented oncogene possessing potent transforming capacity, is not only up-regulated in m...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
The transition of ductal carcinoma in situ (DCIS) to invasive carcinoma (IC) in breast cancer can be faithfully reproduced by the intraductal mouse model. Envisaging to use this model for therapeutic testing, we aimed to in-depth characterize the tumor immunity associated with the differential progression of two types of intraductal tumors. More specifically, we focused on triple-negative breast cancer (TNBC) and intraductally inoculated luciferase-expressing metastatic 4T1 and locally invasive Py230 cells in lactating mammary glands of syngeneic BALB/c and C57BL/6 female mice, respectively. Although the aggressive 4T1 cel...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Breast Cancer | Breast Carcinoma | Breast Needle Aspiration | Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | CT Scan | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Grants | Nuclear Medicine | PET Scan